Venture Global and ConocoPhillips Announce 20-Year LNG Sales and Purchase Agreement

 ARLINGTON, Va. - 

(BUSINESS WIRE) -- Today, Venture Global, Inc. (NYSE: VG) and ConocoPhillips (NYSE: COP) announced a new, long-term Sales and Purchase Agreement (SPA) for liquefied natural gas (LNG). Under the SPA, ConocoPhillips will buy 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030.

"Venture Global is proud to welcome ConocoPhillips, one of the world's leading energy companies, as a long-term partner," said Venture Global CEO Mike Sabel. "This agreement reflects continued market confidence in our proven ability to deliver reliable, low-cost U.S. LNG quickly and at scale. We look forward to supporting ConocoPhillips' growing global LNG portfolio for decades to come."

About Venture Global

Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. The company’s first three projects, Calcasieu Pass, Plaquemines LNG, and CP2 LNG, are located in Louisiana along the Gulf of America. Venture Global is developing carbon capture and sequestration projects at each of its LNG facilities.

Forward-Looking Statements

This press release contains certain statements that may include “forward-looking statements.” All statements, other than statements of historical or present facts or conditions, included herein are “forward-looking statements.” Included among “forward-looking statements” are, among other things, statements regarding Venture Global’s business strategy, plans and objectives. Venture Global believes that the expectations reflected in these “forward-looking statements” are reasonable, however they are inherently uncertain and involve a number of risks and uncertainties beyond Venture Global’s control. In addition, assumptions may prove to be inaccurate. Actual results may differ materially from those anticipated or implied in “forward-looking statements” as a result of a variety of factors. These “forward-looking statements” speak only as of the date made, and other than as required by law, Venture Global undertakes no obligation to update or revise any “forward-looking statement” or provide reasons why actual results may differ, whether as a result of new information, future events or otherwise.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001098196/en/

Permalink

https://www.aetoswire.com/en/news/0210202657758

Contacts

Investor Contact:

Ben Nolan

IR@ventureglobalLNG.com

Media Contact:

Shaylyn Hynes

press@ventureglobalLNG.com

NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising

 

New AI and automation capabilities help retailers close execution gaps and scale merchandising decisions across every store.

 

(BUSINESS WIRE)--NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access.

"Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time building and updating planograms and more time acting on opportunities. With greater automation, retailers can improve productivity, respond faster to change, and make more confident merchandising decisions at scale."

Key client benefits

Work more efficiently with NIQ Optiq: Use conversational AI to create and optimize planograms through natural-language requests within Spaceman, reducing manual effort and helping merchandising teams complete traditionally time-intensive planning tasks more efficiently.

Localize store-specific planograms at scale: Use Spaceman’s automation capabilities to create and maintain store-specific planograms across large store networks, accounting for local market conditions, assortments, and shopper behavior to bring greater localization to the shelf at scale.

Improve execution through AI-powered compliance measurement: Automatically identify execution gaps and compliance issues across stores, reducing manual audits and driving a more consistent shopper experience.

These investments reflect NIQ's broader commitment to embedding trusted AI across retail workflows and delivering cloud-enabled solutions that help retailers move more seamlessly from planning to execution. By connecting intelligent automation, merchandising decisions, and execution measurement, NIQ is helping retailers drive greater efficiency, consistency, and business impact across their operations.

About NIQ

NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action.

With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.

For more information, please visit www.niq.com.

Spaceman® and NIQ® are registered trademarks (NIQ with additional pending applications); NIQ Optiq and The Full View™ are pending trademarks; all of Nielsen Consumer LLC or its affiliates. NielsenIQ® is a registered trademark licensed to NIQ. All other trademarks are the property of their respective owners.

Forward-Looking Statements

This press release may contain forward-looking statements regarding anticipated timelines, benefits, features, and outcomes of the latest Spaceman enhancements. These statements reflect current expectations and projections based on available data, historical patterns, and various assumptions. Words such as 'expects,' 'anticipates,' 'projects,' 'believes,' 'forecasts,' and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future outcomes and are subject to inherent uncertainties, including changes in consumer preferences, economic conditions, technological advancements, and competitive dynamics. Actual results may differ materially from those expressed or implied in these statements. While we strive to base our insights on reliable data and sound methodologies, we undertake no obligation to update any forward-looking statements to reflect future events or circumstances, except to the extent required by applicable law.

© 2026 Nielsen Consumer LLC. All Rights Reserved.

Frequently Asked Questions

Q: What is changing with Spaceman®?

A: NIQ is investing in Spaceman to deliver a more scalable, cloud-enabled, and AI-powered merchandising solution. The latest enhancements combine cloud-based delivery, AI/ML-powered capabilities, and enhanced automation to help retailers and manufacturers plan faster, execute better, and grow smarter while turning merchandising decisions into measurable business outcomes.

Q: Why is NIQ investing in Spaceman?

A: Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior. These investments are designed to reduce manual planning effort, help retailers scale localized merchandising decisions, and improve execution across large store networks.

Q: What makes the latest evolution of Spaceman different?

A: The latest evolution brings conversational AI, planogram automation, modeling, compliance measurement, and cloud-based access together within the Spaceman merchandising workflow. This enables retailers to move more efficiently from planning to store-specific execution while scaling decisions across their store networks.

Q: How does Spaceman help retailers?

A: Spaceman helps retailers create and maintain localized, store-specific planograms at scale, reduce manual planning effort, and improve visibility into merchandising execution and compliance. This helps teams respond more effectively to local market conditions, assortments, and shopper behavior while delivering greater consistency across their store networks.

Q: How does cloud-based access support Spaceman clients?

A: NIQ-managed Azure hosting enables clients to operate Spaceman on NIQ-managed cloud infrastructure, reducing reliance on internal IT resources while improving scalability, deployment speed, and overall platform performance.

Q: What AI capabilities are included in Spaceman?

A: NIQ Optiq brings conversational AI into Spaceman, enabling merchandising teams to use natural-language requests to create and optimize planograms with less manual effort. Spaceman also uses AI and machine learning to support planogram automation and compliance measurement, helping retailers localize merchandising at scale and identify execution gaps across stores.

Q: What is NIQ Optiq in Spaceman?

A: NIQ Optiq brings conversational AI into Spaceman, enabling users to translate natural-language requests into planogram actions. It works with the data already managed within Spaceman and its existing automation and machine learning capabilities to help merchandising teams create and optimize planograms with less manual effort.

Q: Who can benefit from Spaceman?

A: Spaceman is designed for retailers looking to modernize merchandising operations, improve planogram creation and execution, reduce manual effort and IT complexity, and scale localized, data-driven merchandising decisions across their store networks.

Q: What types of business decisions can Spaceman support?

A: Spaceman supports decisions across assortment planning, space planning, store-specific planogram creation, merchandising execution, compliance measurement, and category management. By connecting planning and execution, Spaceman helps retailers make more localized and consistent merchandising decisions across their store networks.

Q: How does Spaceman support NIQ's broader strategy?

A: These investments reflect NIQ's broader commitment to embedding trusted AI across retail workflows and delivering cloud-enabled solutions that help retailers move more seamlessly from planning to execution. By connecting intelligent automation, merchandising decisions, and execution measurement, NIQ is helping retailers drive greater efficiency and consistency across their operations.

Q: Is this the final phase of Spaceman's evolution?

A: No. The latest enhancements represent the next step in NIQ's ongoing investment in Spaceman. NIQ will continue to evolve the platform to help retailers simplify merchandising, improve execution, and respond more effectively to changing market conditions.

NIQ-GENERAL

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001493563/en/

Permalink

https://www.aetoswire.com/en/news/54613412

Contacts

Media contact: Julia Mayer

julia.mayer@nielseniq.com

 

LISTERINE® Launches Oral Care Counts This World Smile Day as Oral Disease Cases Rise to 3.73 Billion

 SUMMIT, N.J. - Thursday, 01. October 2026 AETOSWire Print 

Global research shows oral disease case numbers rose more than 3% over four years, as researchers warn that progress is too slow to meet the WHO’s 2030 target.

This World Smile Day, LISTERINE® is launching Oral Care Counts – a multiyear education and advocacy initiative showing why oral health is an essential part of overall health and how practical daily habits, including a three-step oral care routine of brushing, flossing and rinsing, can support better oral health.

 

(BUSINESS WIRE)--Nearly half the world’s population is affected by oral disease – and the number of cases is rising. This World Smile Day, LISTERINE® is launching Oral Care Counts – a multiyear education and advocacy initiative showing why oral health is an essential part of overall health and how practical daily habits, including a three-step oral care routine of brushing, flossing and rinsing, can support better oral health. The multiyear education and advocacy campaign is designed to help more people understand the essential role oral health plays in overall health and wellbeing, and how realistic daily habits can make prevention more achievable.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001163338/en/

Oral Care Counts aims to bring together healthcare professionals, advocates, policymakers, community organizations, and consumers to raise understanding of oral health as an essential part of overall health and wellbeing. The initiative encourages people to look beyond the smile, consider the health of the whole mouth and understand the role that brushing, flossing and, where appropriate, an essential-oil mouthrinse can play within a more complete daily routine.

As the #1 Dentist Recommended Mouthwash Brand* in the United States, LISTERINE® is bringing more than a century of oral health research and innovation to a simple but important belief: healthy mouths are an essential part of healthy lives.

A growing global challenge – and a narrowing window for action

The systematic analysis, published in The Lancet Public Health, found that cases of the main oral conditions rose 3.07% in four years. These conditions include untreated tooth decay, severe periodontitis, and total tooth loss.¹

The WHO’s Global Oral Health Action Plan calls for a 10% relative reduction in the combined prevalence of the main oral diseases and conditions by 2030, compared with 2019.² A growing and aging global population is a key factor behind rising case numbers, while other pressures are more localized. In many communities, inadequate fluoride exposure, high-sugar foods and limited access to oral health services continue to sustain the wider burden.³ These pressures underline the need for action at several levels – from access to professional care and public health measures, to effective daily self-care such as brushing, flossing and using a clinically proven essential-oil mouthrinse.

Prevention has to work in the real world

JoAnn Gurenlian, RDH, MS, PhD, AAFAAOM, FADHA said:

“Oral health doesn’t exist in isolation: it’s an essential part of overall health and wellbeing. These alarming figures underline a health challenge whose consequences extend far beyond the mouth.

“Brushing twice daily with fluoride toothpaste and flossing are the foundations. For people who need additional support, adding an essential-oil mouthrinse can be a straightforward 30-second third step, completing the routine with clinically demonstrated benefits beyond brushing and flossing alone.⁴–⁶

Making oral care count every day

Oral Care Counts combines education, advocacy, and collaboration to make oral health easier to understand, elevate it as an essential part of overall health and wellbeing, and make everyday prevention more achievable. It will also help people understand the role that mouthrinse can play within a complete oral care routine.

Oral Care Counts will:

Elevate awareness of oral health as an essential part of overall health and wellbeing, and of the role mouthrinse can play within a complete oral care routine, via webinars, training sessions and chairside guides developed for the American Dental Hygienists Association

Support healthcare professionals, including pharmacists, with evidence-based education and practical resources through partnerships such as our pharmacy upskilling program with retail grocery and pharmacy chain, Meijer, and the National Community Pharmacists Association - as we work to reach more patients/consumers in rural communities, and educate them on the importance of preventative oral care.

Help people strengthen daily oral care habits and improve access to preventive information and care through partnerships with organizations such as the National Rural Health Association and Young Minds Inspired.

The campaign reflects the belief that oral care matters for more than fresh breath or appearance. Oral health is an essential part of overall health and wellbeing: a healthy mouth supports everyday comfort, confidence and quality of life, and caring for the mouth is an important part of caring for the whole person.

Brushing and flossing remain essential: where appropriate, adding a LISTERINE® essential-oil mouthrinse as the third step in a complete routine can provide clinically demonstrated additional benefits beyond brushing and flossing alone.⁵˒⁶

Oral Care Counts will be activated in the United States and other key markets globally, with a particular focus on prevention, affordability and access.

Building on a legacy of oral health leadership

For more than 100 years, LISTERINE® has advanced research and innovation to support whole-mouth health. Further strengthening its commitment to meeting evolving consumer preferences, the brand launched a range of intensities earlier this year and, most recently, new LISTERINE® Whitening mouthwash. Designed to fit seamlessly into the daily three-step oral care routine of brushing, flossing, and rinsing, this alcohol-free and peroxide-free mouthwash delivers a superior clean, fresh breath and effective whitening in a gentle formula that strengthens teeth without sensitivity-causing ingredients.

Trusted by more than one billion people worldwide, the brand continues to champion science-backed solutions that help consumers maintain healthier oral care routines every day.

“Through Oral Care Counts, we are bringing together practical education, professional support, and achievable daily habits to help more people take control of their oral health,” said Holly Turner, Global Vice President, LISTERINE® & BAND-AID®. “That includes helping people understand how brushing, flossing and, where appropriate, a clinically proven essential-oil mouthrinse can work together as a complete three-step routine. World Smile Day is the right moment to start the bigger conversation and show why caring for the mouth is an important part of caring for the whole person.”

To learn more about Oral Care Counts, visit Listerine.com/OralCareCounts

About Oral Care Counts

Oral Care Counts is LISTERINE®’s multiyear education and advocacy initiative, developed to elevate oral health as an essential part of overall health and help more people take control of it through practical, effective daily habits, including the role of a clinically proven essential-oil mouthrinse within a complete three-step routine where appropriate.

The initiative engages healthcare professionals, advocates, policymakers, community organizations, and consumers to support evidence-based education, strengthen everyday self-care, increase understanding of the role mouthrinse can play within a complete routine, and improve access to oral health information and preventive care.

For further information, visit Listerine.com/OralCareCounts

About LISTERINE®

For more than a century, LISTERINE® has advanced research and innovation to support oral health. Studies involving LISTERINE® have appeared in hundreds of peer-reviewed publications, supporting its longstanding commitment to science-backed oral care. LISTERINE® is the #1 Dentist Recommended Mouthwash Brand* in the United States and is a brand of Kenvue Brands LLC, a subsidiary of Kenvue Inc.

*IQVIA ProVoice Survey, February 2026 (United States).

About World Smile Day

World Smile Day® is observed annually on the first Friday in October. It was created in 1999 by Harvey Ball, the commercial artist who designed the original smiley face in 1963, as a day dedicated to smiles, kindness and goodwill. Its enduring call to action is: “Do an act of kindness. Help one person smile.” Following Harvey Ball’s death in 2001, the Harvey Ball World Smile Foundation was established to continue his legacy and serves as the official sponsor of World Smile Day®. In 2026, World Smile Day® falls on Friday, October 2.

References

GBD 2023 Oral Disorders Collaborators. Global and regional progress towards reduced burden of oral conditions between 2019 and 2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet Public Health. 2026;11(9e630–e641. doi:10.1016/S2468-2667(26)00143-X. https://pubmed.ncbi.nlm.nih.gov/42612648/

World Health Organization. Global strategy and action plan on oral health 2023–2030. Geneva: World Health Organization; 2024. https://www.who.int/publications/i/item/9789240090538

World Health Organization. Oral health. Fact sheet. Updated March 17, 2025. https://www.who.int/news-room/fact-sheets/detail/oral-health

Chapple ILC, Van der Weijden F, Doerfer C, Herrera D, Shapira L, Polak D, et al. Primary prevention of periodontitis: managing gingivitis. Journal of Clinical Periodontology. 2015;42(Suppl 16) :S71–S76. doi:10.1111/jcpe.12366.

Araujo MWB, Charles CA, Weinstein RB, McGuire JA, Parikh-Das AM, Du Q, et al. Meta-analysis of the effect of an essential oil-containing mouthrinse on gingivitis and plaque. Journal of the American Dental Association. 2015;146(8):610–622. doi:10.1016/j.adaj.2015.02.011.

Sharma N, Charles CH, Lynch MC, Qaqish J, McGuire JA, Galustians JG, et al. Adjunctive benefit of an essential oil-containing mouthrinse in reducing plaque and gingivitis in patients who brush and floss regularly: a six-month study. Journal of the American Dental Association. 2004;135(4):496–504. doi:10.14219/jada.archive.2004.0217.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001163338/en/

Permalink

https://www.aetoswire.com/en/news/54613730

Contacts

Media Contacts

Annette Reichel

areiche1@kenvue.com

917-664-7114

Meghan Harding

mhardin1@kenvue.com

904-417-3336

 

Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates

INCHEON, Korea & TEL AVIV, Israel - Thursday, 01. October 2026

The agreement covers SB41, a potential biosimilar candidate referencing Fasenra® (benralizumab), and SB44, a potential biosimilar candidate referencing Ilaris® (canakinumab) with an option for 4 additional assets

The partnership will cover development and commercialization in the United States, Europe, and Canada, with an option to expand to other territories

The partnership brings together Samsung Bioepis’ development, regulatory and manufacturing capabilities with Teva’s global commercial reach to advance the investigational biosimilar candidates and help bring additional important treatment options to patients worldwide

 

(BUSINESS WIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizumab), and SB44, a biosimilar candidate referencing Ilaris®2 (canakinumab).

Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, and manufacture of the biosimilars, while Teva will be responsible for commercialization in global markets, including the United States (U.S.), Europe, and Canada. The companies have agreed to an option for expanding the partnership to other territories.

This agreement reinforces the long-standing and successful partnership between Samsung Bioepis and Teva, which has already resulted in the successful commercialization of EPYSQLI® (eculizumab-aagh) in the U.S. The companies have also expanded that agreement further to include OPUVIZ® (aflibercept) in Canada. The expanded collaboration reflects a shared approach to combining complementary capabilities for broadening access to biosimilar medicines across global markets.

“We are thrilled to expand our successful partnership with Teva with these new biosimilar candidates. This agreement marks another milestone in our shared journey to improve patient access to life-changing medicines,” said Kyung-Ah Kim, President and Chief Executive Officer at Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and healthcare systems across the world.”

Richard Francis, President and CEO of Teva said, “Biosimilars are an increasingly important part of our Pivot to Growth strategy and our ambition to transform into a leading biopharmaceutical company. This global multi-product agreement is a significant step in scaling our biosimilars business, adding greater breadth to our pipeline and building on the strong foundation we have established with Samsung Bioepis in the U.S. By combining a strong and growing portfolio and our excellent global commercial capabilities, we are strengthening our leadership position in biosimilars and our ability to bring more treatment options to patients around the world.”

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings (KRX: 0126Z0), Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit https://www.tevapharm.com.

Teva Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute the license, development and commercialization agreement with Samsung Bioepis; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ending December 31, 2025, including in the section captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

1 Fasenra is a trademark of AstraZeneca AB.

2 Ilaris is a trademark of Novartis AG.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001835078/en/

Permalink

https://www.aetoswire.com/en/news/0110202657731

Contacts

MEDIA CONTACT

Samsung Bioepis Media Inquiries:

Anna Nayun Kim, nayun86.kim@samsung.com

Yoon Kim, yoon1.kim@samsung.com

Teva Media Inquiries:

TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquiries:

TevaIR@Tevapharm.com

Global Health Leaders to Convene at Abu Dhabi Future Health Summit 2026

 Abu Dhabi Future Health Summit will convene leaders across healthcare, science, technology, policy, and investment from 20-22 October at ADNEC Centre Abu Dhabi

Under the 2026 theme ‘To Sense is to Predict’, the Future Health Summit will examine how greater health insight can enable earlier intervention and better outcomes

AstraZeneca CEO Sir Pascal Soriot, Isomorphic Labs President Mr. Max Jaderberg, Amref Health Africa Group CEO Dr. Githinji Gitahi, and Health Ministers from Kosovo, Montenegro, Serbia and Colombia are among more than 130 Forum speakers, with participation expected from 100 countries

 

(BUSINESS WIRE)--Global leaders across healthcare, science, technology, policy, and investment will convene at the Abu Dhabi Future Health Summit from 20 to 22 October 2026 to examine how health systems can better anticipate risk and enable earlier intervention as advances in AI, genomics, diagnostics, and health data create new possibilities for understanding health risks earlier.

As health systems respond to the growing burden of chronic disease and the need to help people live longer in good health, the ability to identify changing health risks and act sooner is becoming increasingly important. Hosted by Future Health – A Global Initiative by Abu Dhabi and the Department of Health – Abu Dhabi, the Future Health Summit will be held under the theme 'To Sense is to Predict', exploring the global shift from reactive models of care towards earlier prediction, prevention, and personalised intervention.

Future Health is already translating this ambition into year-round activity. Its inaugural Future Health Challenge received 393 submissions from 68 countries with solutions already present in international communities. Additionally, the platform has released the Future of Longevity and Future of Healthy Living whitepapers, and joined the MIT Koch Institute for Integrative Cancer Research’s BioConvergence Cancer Alliance as a Founding Member. The Future Health Summit will build on this work, bringing the Future Health community together in Abu Dhabi to advance further collaboration and implementation.

With 130 Forum speakers and more than 175 exhibitors, with representation expected from 100 countries, the Summit will bring together expertise from a wide range of health systems and settings to examine how emerging approaches can work across different populations and models of care.

Featured Forum speakers include:

His Excellency Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi

Sir Pascal Soriot, CEO of AstraZeneca

Mr. Tim Schmid, EVP & Worldwide Chairman of Johnson & Johnson MedTech

Ms. Helga Fogstad, Director of Health, UNICEF

Mr. Will Ahmed, Founder & CEO of WHOOP

Mr. Tom Hale, CEO of ŌURA

Dr. Christine Yuan Huang, Founder & CEO of Quantum Life

Mr. Max Jaderberg, President of Isomorphic Labs

Dr. Ola Brown, Founding Partner of HealthCap Africa

Dr. Jayasree Iyer, CEO of Access to Medicine Foundation

Mr. Hugo Harper, Mission Director of a Healthy Life at Nesta

They will be joined by international ministers and government representatives. This global participation brings experience of national health systems and organisations to the discussions in Abu Dhabi, reflecting the reach of the Future Health community.

Her Excellency Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: “The ability to understand health risk earlier can have a measurable impact on how health systems serve their populations. As advances in science and technology give us greater insight into health, the priority is to translate that insight into earlier action that can improves outcomes and help people live more years in good health.

“Global collaboration is fundamental to advancing this approach across different health systems and contexts. The Abu Dhabi Future Health Summit brings international expertise together with the capabilities we have built in Abu Dhabi, creating opportunities compare experience across health systems and examine how new approaches can work in practice. Abu Dhabi provides a real-world environment where that global exchange can connect directly with implementation at population scale,” she added.

At the core of the Summit is the Forum, which will feature keynotes, C-suite conversations, and public-private dialogues involving leaders from across the global health ecosystem. The Forum will explore ‘To Sense is to Predict’ at three interconnected levels - individual, health system, and population - with discussions spanning Future Health’s four thematic focus areas: Longevity and Precision Medicine; Digital Health & AI; Health System Resilience & Sustainability; and Investment in Life Sciences.

Alongside the Forum, the Global Exhibition will bring together exhibitors from across healthcare, technology, life sciences, and investment, showcasing innovations and capabilities shaping the future of health. A programme of Side Events will provide further opportunities for focused dialogue and collaboration.

The Abu Dhabi Future Health Summit is the annual flagship gathering of Future Health – A Global Initiative by Abu Dhabi, a year-round platform for global collaboration and transformative health innovation. Throughout 2026, Future Health has advanced the ‘To Sense is to Predict’ agenda through international dialogues, research and impact initiatives designed to move ideas towards real-world application.

A full list of Forum speakers, which will continue to be updated in the lead up to the event, is available on the Future Health website.

Register as a visitor: Future Health Summit Visitor Registration

Media registrations are welcome at: Future Health Summit Media Registration

About Future Health – A Global Initiative by Abu Dhabi

Future Health is a year-round platform for global collaboration and transformative health innovation, held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council.

Bringing together health researchers, policymakers, business leaders, investors and entrepreneurs from across disciplines and geographies, Future Health drives collective action to strengthen health systems and unlock longer, healthier lives for all.

Through a year-round programme of research insights, publications, impact initiatives, Challenges, R&D funding, and cross-sector convenings, Future Health advances progress across four focus areas: longevity and precision medicine, health systems and sustainability, digital health and AI, and investment in life sciences.

Future Health is curated and convened by the Department of Health – Abu Dhabi and its Founding Partners PureHealth, M42, Institute for Healthier Living Abu Dhabi, and Mubadala Bio. Mediclinic Middle East serves as Strategic Partner and Burjeel Holdings as Associate Partner.

For more information, visit www.futurehealthinitiative.ae⁠ and follow Future Health on: X, Instagram, LinkedIn and Facebook.

About the Department of Health – Abu Dhabi (DoH):

The DoH is the regulatory body of the healthcare sector at the Emirate of Abu Dhabi and ensures excellence in healthcare by monitoring the health status of the population. DoH defines the strategy for the health system, monitors and analyses the health status of the population and performance of the system. In addition, DoH shapes the regulatory framework for the health system, inspects against regulations, enforces standards, and encourages adoption of world-class best practices and performance targets by all healthcare service providers in the Emirate. DoH also drives programmes to increase awareness and adoption of healthy living standards among the residents of the Emirate of Abu Dhabi in addition to regulating scope of services, premiums and reimbursement rates of the health system.

For further information on DOH, visit https://www.doh.gov.ae/ and follow on Twitter, Instagram, Facebook, LinkedIn and YouTube.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001283179/en/

Permalink

https://aetoswire.com/en/news/54614269

Contacts

 

Media Enquiries

For media enquiries, interview requests and accreditation opportunities, please contact: media@futurehealthinitative.ae

MidOcean Concludes 2026 Equity Raise, Securing More Than $4 Billion of Equity Commitments to Accelerate Global LNG Growth Strategy

 (BUSINESS WIRE) -- MidOcean Energy ("MidOcean" or the "Company"), a liquefied natural gas (LNG) company formed and managed by EIG, today announced the conclusion of its 2026 equity capital raise, securing more than $4 billion of closed and pending commitments over the last 12 months from new strategic and institutional investors, as well as significant re-ups from existing investors. The capital committed significantly exceeded the Company's original target of $2 billion, reflecting continued confidence in MidOcean's strategy, portfolio, team and long-term growth outlook.

The raise includes commitments from strategic investors, sovereign-linked institutions and financial investors. Among the new investors are the Private Department of Sheikh Mohammed bin Khalid Al Nahyan, Idemitsu Kosan, NYK Line (through Diamond Gas MidOcean), The Arab Energy Fund, Shizuoka Gas and certain Korean institutional investors.

The proceeds are expected to enhance MidOcean's balance sheet flexibility and position the Company to pursue a pipeline of LNG growth opportunities encompassing both cash flowing and development assets. MidOcean has assembled an LNG portfolio spanning Canada, Australia, the U.S., and Latin America and continues to evaluate accretive opportunities consistent with its disciplined investment approach.

R. Blair Thomas, Chairman of MidOcean and Chief Executive Officer of EIG, said:

"The progress achieved in this capital raise represents a major milestone for MidOcean and supports our strategy of building a scaled, diversified and resilient global LNG platform. We are pleased to welcome a distinguished group of new investors and thank our existing shareholders for their continued support and confidence."

"We believe LNG will continue to play an essential role in supporting energy security and global economic growth, and that MidOcean is well positioned to benefit from these long-term market fundamentals. Current events also highlight the importance of geographic diversification with the ability to reliably serve clients from multiple delivery points."

De la Rey Venter, Chief Executive Officer of MidOcean, said:

"In just a few years, MidOcean has grown from concept to a fully integrated global LNG platform, and this capital raise further strengthens our financial flexibility and positions us to continue advancing our robust growth strategy. We have built a high-quality LNG portfolio with strong cash flow characteristics and meaningful growth optionality, and we are well positioned to move decisively on the pipeline of opportunities we have identified. We look forward to building on this momentum and creating value for our investors."

About EIG

EIG is a leading institutional investor in the global energy and infrastructure sectors with $27.1 billion in assets under management as of June 30, 2026. EIG specializes in private investments in energy and energy-related infrastructure on a global basis. During its 44-year history, EIG has committed over $55 billion to the energy sector through 429 projects or companies in 44 countries on six continents. EIG’s clients include many of the leading pension plans, insurance companies, endowments, foundations and sovereign wealth funds in the U.S., Asia and Europe. EIG is headquartered in Washington, D.C. with offices in Houston, London, Sydney, Rio de Janeiro, Hong Kong and Seoul. For additional information, please visit EIG’s website at www.eigpartners.com.

About MidOcean Energy

MidOcean Energy, a pure play LNG company formed and managed by EIG, seeks to build a diversified, resilient, cost- and carbon-competitive global LNG portfolio. It reflects EIG’s belief in LNG as a critical element of a lower-carbon, competitive and more secure global energy system. MidOcean has established a platform with interests in LNG projects across the US, Latin America, Canada and Australia, supported by a global footprint including an LNG shipping and marketing office in Singapore and corporate headquarters in London. For additional information, please visit www.midoceanenergy.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001738066/en/

Permalink

https://www.aetoswire.com/en/news/0110202657733

Contacts

EIG/MidOcean Contact Information

FGS Global

Kelly Kimberly / Brandon Messina

+1 212-687-8080

EIG@fgsglobal.com

 

Andersen Global Enhances Pakistan Legal Presence with New Member Firm

 SAN FRANCISCO - Thursday, 01. October 2026 AETOSWire Print 

(BUSINESS WIRE) -- Andersen Global strengthens its legal presence in Pakistan as Samdani & Qureshi, a collaborating firm since 2021, rebrands to Andersen Legal in Pakistan and is the latest member firm to join the organization.

Headquartered in Islamabad, Andersen Legal in Pakistan advises domestic and international clients, including businesses, investors, financial institutions, public sector entities, development organizations, and individuals, on legal, commercial, and regulatory matters. The firm also handles arbitration and dispute resolution, advising on complex transactions, investments, finance, projects, and contentious matters in Pakistan and across borders.

“Our approach is grounded in senior attention, clear communication, and disciplined analysis, with a focus on delivering advice that clients can put into action,” said Nudrat Ejaz Piracha, partner at Andersen Legal in Pakistan. “Joining Andersen Global enables us to build on this approach by drawing on additional capabilities and perspectives, while continuing to help clients manage risk, preserve value, and support long-term growth.”

“As businesses pursue investment and growth opportunities in Pakistan, they increasingly require legal counsel that understands both the local environment and the broader commercial context,” said Mark L. Vorsatz, global chairman and CEO of Andersen. “Andersen Legal in Pakistan brings a broad legal practice and an experienced team that will further strengthen our capabilities and support clients throughout the Southern Asia region.”

Andersen Global is an international association of legally separate, independent member firms comprised of tax, legal, and valuation professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 50,000 professionals worldwide and a presence in over 1,000 locations through its member firms and collaborating firms.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001015747/en/

Permalink

https://www.aetoswire.com/en/news/0110202657743

Contacts

Megan Tsuei

Andersen Global

415-764-2700